Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks
  Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com Australia
  Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company - Business Wire
  Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - Yahoo Finance
  35-year Industry-Academic Partnership Yielding Groundbreaking Advances for Science and Patients Renews for Another Three Years Between La Jolla Institute for Immunology and Kyowa Kirin – lji.org - La Jolla Institute for Immunology
  Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - PR Newswire
  Kura Oncology and Kyowa Kirin Announce FDA Acceptance of New Drug Application for Ziftomenib in Relapsed or Refractory AML with NPM1 Mutation - Nasdaq
  Kyowa Kirin constructs drug manufacturing facility in Japan - Pharmaceutical Technology